Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 5Active not recruiting 3Terminated 2Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

NSCLC Harboring NRG1 Fusion 1Mouth Neoplasms 1Melanoma 1Lung Neoplasms 1

Interventions

pembrolizumab 28Carboplatin 13Nivolumab 12Cisplatin 12atezolizumab 10Paclitaxel 10venetoclax 9Ipilimumab 9Radiotherapy 8Pemetrexed 8Docetaxel 8fludarabine 7durvalumab 7Specimen Handling 7Gemcitabine 7Cyclophosphamide 7Bevacizumab 7fludarabine phosphate 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6tislelizumab 5enzalutamide 5Trastuzumab 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5tazemetostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Afatinib × 90 days × Clear all
NCT06897735 2026-06-03

EDDIS-a1

Petrov, Andrey

Phase 1 Terminated
4 enrolled
DermatologicHead & NeckThoracic

Lung Neoplasms, Melanoma, Mouth Neoplasms

NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Partner Therapeutics, Inc.

Phase 2 Terminated
13 enrolled
GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡